Skip to main content
    B

    BeiGene, Ltd. (ONC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $374.08
    +22.60 (+6.43%)

    Market Cap: $39.99B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(22/37)
    Avg Surprise
    +22.00%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$1.88
    Range$1.56 - $2.24
    12 analysts
    EPS Revisions
    7
    0
    7d
    7
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$1.69+10.8%
    60d ago$1.82+3.3%
    30d ago$1.82+3.2%
    7d ago$1.85+1.3%
    Current$1.88
    Revenue Consensus
    $1.8B
    Range$1.7B - $1.8B
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$3.33
    Range$2.32 - $4.51
    17 analysts
    Revenue Consensus
    $2.0B
    Range$1.9B - $2.3B
    31 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.33---
    Sep 26EST
    		-$1.88---
    Jun 26
    Reported Aug 5
    		$2.05$1.40+46.43%Beat+144.0%
    Mar 26
    Reported May 6
    		$1.96$0.81+141.98%Beat+19500.0%
    Dec 25
    Reported Feb 26
    		$0.58N/A-63.75%Miss+140.6%
    Sep 25
    Reported Nov 6
    		$1.09$0.86+26.74%Beat+194.8%
    Jun 25
    Reported Aug 6
    		$0.84$0.26+223.08%Beat+173.0%
    Mar 25
    Reported May 7
    		$0.01N/A+101.35%Beat+100.4%
    Dec 24
    Reported Feb 27
    		$-1.43$-1.01-41.58%Miss+58.9%
    Sep 24
    Reported Nov 12
    		$-1.15$-1.11-3.60%Miss-157.2%
    Jun 24
    Reported Aug 7
    		$-1.15$-2.14+46.26%Beat+68.4%
    Mar 24
    Reported May 8
    		$-2.41$-2.92+17.47%Beat+27.8%
    Dec 23
    Reported Mar 30
    		$-3.48$-3.45-0.87%Miss+18.9%
    Sep 23
    Reported Nov 9
    		$2.01$-2.93+168.60%Beat+137.3%
    Jun 23
    Reported Aug 2
    		$-3.64$-2.98-22.15%Miss+34.5%
    Mar 23
    Reported Jun 29
    		$-3.34$-3.66+8.74%Beat+21.2%
    Dec 22
    Reported Mar 31
    		$-4.29$-4.35+1.38%Beat+30.4%
    Sep 22
    Reported Nov 9
    		$-5.39$-3.77-42.97%Miss-20.9%
    Jun 22
    Reported Aug 4
    		$-5.56$-4.01-38.65%Miss-6.3%
    Mar 22
    Reported Jun 29
    		$-4.24$-4.47+5.15%Beat-714.5%
    Dec 21
    Reported Mar 30
    		$-6.16$-6.16+0.00%Beat-18.5%
    Sep 21
    Reported Nov 4
    		$-4.46$-4.70+5.11%Beat+7.3%
    Jun 21
    Reported Aug 5
    		$-5.23$-3.99-31.08%Miss-21.3%
    Mar 21
    Reported Jun 29
    		$0.69N/A+141.82%Beat+114.7%
    Dec 20
    Reported Mar 30
    		$-5.20$-5.20+0.00%Beat+18.6%
    Sep 20
    Reported Nov 5
    		$-4.81$-4.18-15.07%Miss+5.9%
    Jun 20
    Reported Aug 6
    		$-4.31$-4.72+8.69%Beat-201.4%
    Mar 20
    Reported Jun 29
    		$-4.70$-4.85+3.09%Beat-67.3%
    Dec 19
    Reported Mar 30
    		$-6.39$-6.39+0.00%Beat-41.4%
    Sep 19
    Reported Nov 12
    		$-5.11$-3.56-43.54%Miss-102.0%
    Jun 19
    Reported Aug 8
    		$-1.43N/A+52.49%Beat+51.0%
    Mar 19
    Reported Jun 29
    		$-2.81$-3.14+10.51%Beat-38.4%
    Dec 18
    Reported Mar 30
    		$-4.52$-2.79-62.01%Miss-170.5%
    Sep 18
    Reported Nov 7
    		$-2.53$-2.97+14.81%Beat-199.6%
    Jun 18
    Reported Aug 9
    		$-2.92$-2.12-37.74%Miss-92.1%
    Mar 18
    Reported Jun 29
    		$-2.03$-1.74-16.67%Miss-59.8%
    Dec 17
    Reported Mar 30
    		$-1.67N/AN/ABeat-166.9%
    Sep 17
    Reported Nov 13
    		$2.54$-1.39+282.73%Beat-
    Jun 17
    Reported Aug 9
    		$-1.52$-1.20-26.67%Miss-
    Mar 17
    Reported Jun 29
    		$-1.27$-0.87-45.98%Miss-
    Dec 16
    Reported Mar 30
    		$-0.63N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio65.86EV/EBITDA33.89x
    Price/FCF34.86xFCF Yield2.87%
    Profitability
    Profit Margin10.70%Operating Margin19.10%
    ROE14.70%ROIC12.15%
    Financial Health
    Debt/Equity0.21xInterest Coverage6.84x
    Current Ratio3.40xQuick Ratio3.06x
    Trading Statistics
    Beta0.61Avg Volume384.10K
    52-Week High$385.2252-Week Low$253.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$357.62
    SMA 20$360.18
    SMA 50$359.43
    SMA 200$322.22
    EMA 10$358.46
    EMA 20$358.31
    EMA 50$351.82
    EMA 200$325.82

    MACD

    Line: 0.69Signal: 0.89Hist: -0.19

    ADX

    ADX: 12.6+DI: 30.5-DI: 25.0

    Aroon & PSAR

    Aroon Up56.0
    Aroon DownN/A
    PSAR$340.44

    Bollinger Bands

    Upper Band$374.40
    Lower Band$345.96
    %B Position790%(Upper)
    Band Width0.99

    RSI (14-Day)

    Neutral
    61.6

    Momentum Oscillators

    Stoch %K49.3
    Stoch %D35.6
    Williams %R-6.7
    ROC (10d)4.3%
    Momentum15.31
    CCI (20d)109.0
    MFI (14d)56.3

    Volatility Measures

    ATR (14d)$10.78(2.9%)
    StdDev (20d)7.11
    Hist Vol34.0%(Moderate)

    Volume Flow

    VWAP$368.78
    OBV3.4M
    AD Line6.5M
    CMF (20d)0.295

    Volume Metrics

    Avg Vol (20d)390.4K
    Vol Ratio1.8x(High)
    VWMA (20d)$360.90

    Pivot Points

    R3$367.33
    R2$361.55
    R1$356.51
    Pivot Point$350.73
    S1$345.69
    S2$339.91
    S3$334.87

    Advanced Oscillators

    TSI2.08
    Ultimate Osc59.0
    KST-2.26

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.71B$1.51B$1.50B$1.41B$1.32B$1.12B$1.13B$1.00B$929.17M$751.65M$634.41M$781.31M
    Cost of Revenue$174.53M$167.22M$142.42M$196.51M$164.61M$165.00M$160.56M$170.46M$138.13M$124.94M$105.83M$96.31M
    Gross Profit$1.53B$1.35B$1.36B$1.22B$1.15B$952.28M$967.26M$831.14M$791.03M$626.72M$528.58M$685.00M
    Operating Expenses$1.21B$1.10B$1.17B$1.05B$1.06B$941.17M$1.05B$951.40M$898.20M$888.07M$912.37M$818.97M
    R&D$612.28M$541.22M$615.42M$523.66M$524.90M$481.89M$542.01M$496.18M$454.47M$460.64M$493.99M$453.26M
    SG&A$593.21M$555.10M$555.29M$529.00M$537.91M$459.27M$504.68M$455.22M$443.73M$427.43M$416.55M$365.71M
    Operating Income$325.05M$249.90M$185.03M$163.11M$87.89M$11.10M$-79,425,000$-120,265,000$-107,161,000$-261,348,000$-383,795,000$-133,968,000
    Interest Income$27.90M$27.66M$58.13M$3.03M$3.50M$5.85M$7.81M$10.64M$13.22M$16.16M$0$26.65M
    Interest Expense$39.74M$32.89M$58.23M$15.95M$8.00M$7.00M$5.93M$0$0$0$0$0
    Income Before Tax$312.46M$259.21M$149.24M$147.16M$99.55M$20.90M$-85,351,000$-98,304,000$-105,920,000$-243,426,000$-350,772,000$229.34M
    Income Tax Expense$75.45M$31.86M$82.74M$22.32M$5.23M$19.63M$66.53M$23.05M$14.48M$7.72M$16.78M$13.93M
    Net Income$237.01M$227.36M$66.50M$124.84M$94.32M$1.27M$-151,881,000$-121,350,000$-120,405,000$-251,150,000$-367,553,000$215.41M
    EBITDA$392.71M$333.25M$248.97M$184.45M$135.16M$60.71M$-35,105,000$-27,012,000$-81,810,000$-218,133,000$-326,953,000$250.85M
    EBIT$352.20M$292.10M$212.99M$147.16M$99.55M$27.90M$-85,351,000$-98,304,000$-105,920,000$-243,426,000$-350,772,000$229.34M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ONC

    News

    Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $420

    Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a price target of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.

    Moomoo•10/9/26•Bullish

    J.P. Morgan Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $445

    J.P. Morgan has reiterated its Buy rating for BeiGene (ONC.US) and increased its target price to $445. This positive adjustment by the investment bank reflects continued confidence in the biopharmaceutical company's...

    Moomoo•10/1/26•Bullish

    BeiGene(ONC.US) Director Sells US$11.32 Million in Common Stock

    A director at BeiGene (ONC.US) has sold 68,000 shares of common stock for a total of US$11.32 million. This transaction occurred at an average price of US$166.45 per share.

    Moomoo•9/30/26•Somewhat-Bearish

    BeOne Medicines (ONC) Rebrand Puts Its Growth Story In Focus On A Higher Fair Value

    BeOne Medicines (ONC) has garnered attention following its rebrand from BeiGene, Ltd. in May 2025, maintaining a strong oncology focus. While the company's strong revenue growth and a fair value of $433.02 suggest it is...

    Simply Wall Street•9/26/26•Bullish

    BeiGene stock gains 2.16 percent as biotech shares rise

    BeiGene stock increased by 2.16 percent in Hong Kong trading on September 22, 2026, as the broader biotechnology sector also saw gains. While this reflects a positive market signal...

    AD HOC NEWS•9/22/26•Neutral

    ONC Valuation and Fair Value

    P/E
    65.9x
    Forward P/E
    35.2x
    EV/EBITDA
    33.9x
    P/FCF
    34.9x
    PEG
    0.8x
    P/B
    8.4x
    See GNG's fair value

    ONC Profitability: Margins, ROIC and FCF

    Gross margin
    88.9%
    Operating margin
    19.1%
    Net margin
    10.7%
    ROIC
    12.1%
    ROE
    14.7%
    FCF margin
    20.3%
    FCF yield
    2.9%

    ONC Competitors

    CompanyTicker
    IDEXX Laboratories IncIDXX
    Centene CorpCNC
    Illumina IncILMN
    Biogen IncBIIB
    Revolution Medicines IncRVMD
    Royalty Pharma PlcRPRX
    Haleon plcHLN
    ResMed IncRMD

    Sector: Healthcare

    ONC Analyst Ratings

    Consensus
    Buy
    Analysts
    28
    Strong Buy
    7
    Buy
    20
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ONC Bull Case vs Bear Case

    Bull case

    • ONC converts 20.3% of revenue into free cash flow.
    • ONC grew quarterly revenue 29.6% year over year.
    • 96.4% of ONC's analyst ratings are Buy or Strong Buy.

    Bear case

    • ONC trades at 65.9x trailing earnings.

    ONC Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    53.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $1.88
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    7 up, 3 down

    Frequently Asked Questions About ONC

    Does ONC pay dividends?

    BeiGene, Ltd. (ONC) does not currently pay a regular dividend.

    What is ONC's P/E ratio?

    BeiGene, Ltd. has a price-to-earnings (P/E) ratio of 65.86.

    What is ONC's market cap?

    BeiGene, Ltd. (ONC) has a market capitalization of $39.99B with a current stock price of $374.08.

    Related stocks

    Sector: Healthcare

    All stocks starting with O

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In